share_log

健康元(600380.SH):丙酸氟替卡松雾化吸入用混悬液获得药品注册证书

Health Source (600380.SH): Fluticasone propionate suspension for atomized inhalation obtained a drug registration certificate

Gelonghui Finance ·  May 27 06:03

On May 27, Ge Longhui Health Yuan (600380.SH) announced that Shanghai Fangyu Health Pharmaceutical Technology Co., Ltd. (abbreviation: Shanghai Fangyu), a holding subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration. This product is an inhaled glucocorticoid (ICS) drug. It has been independently developed by Shanghai Fangyu and is included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue”. Fluticasone propionate is a synthetic trifluoride corticosteroid with anti-inflammatory activity. It has pharmacological advantages such as high lipophilicity and strong receptor affinity. In vitro studies have shown that fluticasone propionate has an affinity for human glucocorticoid receptors more than 3 times that of budesonide.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment